Alzheimer’s Type Neurodegeneration. Possible Correction of Memory Impairment with Intravenous Administration of Exosomes

 Now to get your doctors and hospital to do their jobs. Solve stroke. They need to get human testing going on this.

Alzheimer’s Type Neurodegeneration. Possible Correction of Memory Impairment with Intravenous Administration of Exosomes

• R. A. Poltavtseva,
• N. V. Bobkova,
• D. Yu. Zhdanova,
• E. V. Svirshchevskaya &
• G. T. Sukhikh 

Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology volume 15, pages 306–318 (2021)Cite this article

• Metrics details

Abstract

Alzheimer’s disease (AD) remains one of the socially significant pathologies still lacking effective therapy. The purpose of this work was to analyze the efficacy of the intravenous (i.v.) administration of exosomes obtained from human umbilical cord Wharton jelly multipotent mesenchymal stromal cell culture supernatant. Exosomes were isolated by column filtration and characterized by the expression of specific markers and in vitro binding to mouse fibroblast cells L929. Using a model of the sporadic form of AD, it was shown that i.v. administration of exosomes prevented the deterioration of spatial memory in olfactory bulbectomized mice (OBE). The therapeutic effect was possibly due to the ability of exosomes to penetrate the brain–blood barrier of OBE animals, which was confirmed by visualization of fluorescently labeled exosomes in the cortex and hippocampus after i.v. administration of exosomes.

This is a preview of subscription content, access via your institution.